Rodin Therapeutics Tackles Epigenetics in CNS Disorders

Cambridge, MA-based Rodin Therapeutics has secured $12.9M in series A funding to bring its small molecule epigenetic modulators from preclinical studies in humans. The company was launched last year with the backing of Atlas Ventures and Johnson & Johnson Development Corp., who are also leading this round of funding. The company’s lead compound is a modulator of an epigenetic target that regulates transcription of genes involved in memory, and has been shown in preclinical studies to improve performance on learning and memory tasks. In addition to developing their own pipeline of modulators, they have also in-licensed promising compounds from the Broad Institute. As primary indications, Rodin aims to treat Alzheimer’s disease, but other neurological disorders are also on the horizon.

Cambridge, MA-based Rodin Therapeutics has secured $12.9M in series A funding to bring its small molecule epigenetic modulators from preclinical studies in humans. The company was launched last year with the backing of Atlas Ventures and Johnson & Johnson Development Corp., who are also leading this round of funding. The company’s lead compound is a modulator of an epigenetic target that regulates transcription of genes involved in memory, and has been shown in preclinical studies to improve performance on learning and memory tasks. In addition to developing their own pipeline of modulators, they have also in-licensed promising compounds from the Broad Institute. As primary indications, Rodin aims to treat Alzheimer’s disease, but other neurological disorders are also on the horizon.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail